TrialThe Lancet. Microbe2026

Tecovirimat treatment of clade II mpox: a virological analysis of a randomised, double-blind, phase 3 trial.

Dariia Vyshenska et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.